Objective: Parkinson’s disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have been forwarded to explain the neuronal loss among which chronic neuroinflammation, mitochondrial dysfunction, are of chief importance. However the molecular mechanisms of neurodegeneration are still controversial and proper mechanism is yet to be elucidated.
Background: Inflammation in the brain has become an important factor in driving microglial-mediated release of inflammatory cytokines. NLRP3 is the most extensively researched inflammasomes complex in connection with PD and is the main perpetrator behind the production of active IL-1β and IL-18. Mitochondrial dysfunction has became a key pathophysiological process in several neurodegenerative disorders including PD, where damaged mitochondria produces large amount reactive oxygen species (ROS) and other sterile insults which positively regulate NLRP3 inflammasome activation. Hence inhibiting ROS generation might provide a prospective therapy in controlling inflammasome activation.
Method: Mouse microglia (N9) cells were treated with lipopolysaccharide (LPS) and 1-Methyl-4-phenylpyridinium (MPP+) to activate the NLRP3 Inflammasome complex. MPP+ was used as a mitochondrial complex-I inhibitor which causes generation of large amount of ROS and other insults which activate inflammasome complex. Similarly in animal model MPTP was given to cause neuronal damage in the substantia nigra par compacta (SNpc) region of the brain. Andrographolide treatment was given in both in-vitro and in-vivo models to evaluate its anti-inflammatory activity.
Results: Andrographolide treatment ameliorates motor deficits and dopamine reduction in MPTP treated mice. NLRP3 inhibition by Andrographolide abrogates microglial activation both in vitro and in vivo model. MPTP mediated mitochondrial superoxide generation was responsible for NLRP3 inflamasomes in microglia both in-vitro and in-vivo model. Impaired mitochondrial dysfunction and clearance was seen to further aggravate microglia activation which was ameliorated by Andrographolide treatment.
Conclusion: Collectively, our findings disclose that Andrographolide can inhibit microglial activation by inhibiting ROS generation which might be a promising future therapeutic target for PD.
References: 1. Poewe, W., et al., Parkinson disease. Nat Rev Dis Primers, 2017. 3: p. 17013. 2. Block, M.L., L. Zecca, and J.-S. Hong, Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience, 2007. 8(1): p. 57-69. 3. Liu, J., et al., Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy, 2018. 14(5): p. 845-861. 4. Schrag, A., et al., Predicting diagnosis of Parkinson’s disease: A risk algorithm based on primary care presentations. Movement Disorders, 2019. 34(4): p. 480-486. 5. Sorrentino, Z.A., B.I. Giasson, and P. Chakrabarty, α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta neuropathologica, 2019: p. 1-21. 6. Lourbopoulos, A., A. Ertürk, and F. Hellal, Microglia in action: how aging and injury can change the brain’s guardians. Frontiers in cellular neuroscience, 2015. 9: p. 54. 7. Amroyan, E., et al., Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation. Phytomedicine, 1999. 6(1): p. 27-31. 8. Puri, A., et al., Immunostimulant agents from Andrographis paniculata. Journal of Natural Products, 1993. 56(7): p. 995-999. 9. Zhou, J., et al., Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells. Autophagy, 2012. 8(3): p. 338-349. 10. Guo, W., et al., Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy, 2014. 10(6): p. 972-985.
To cite this abstract in AMA style:
S. Ahmed, V. Naidu. Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/andrograholide-protect-microglial-activation-via-inhibiting-mitochondrial-ros-generation-and-nlrp3-inflammasome-activation-in-in-vitro-and-in-vivo-model-of-parkinsons-disease/. Accessed November 21, 2024.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/andrograholide-protect-microglial-activation-via-inhibiting-mitochondrial-ros-generation-and-nlrp3-inflammasome-activation-in-in-vitro-and-in-vivo-model-of-parkinsons-disease/